Requip 5 mg (Ropinirole Hydrochloride)

Adult dose

1. An appropriate dose should be recommended for each patient, taking efficacy and tolerability into consideration. To improve gastrointestinal tolerability, it is preferable to take the medication with food 3 times daily. Initial therapy: Take 0.25mg 3 times daily. The treatment regimen for the first 4 weeks is as follows: Week 1 2 3 4 Dose per administration (mg) 0.25 0.5 0.75 1.0 Daily dose (mg) 0.75 1.5 2.25 3.0 Maintenance therapy: After initial therapy, the dose may be increased at 1-week intervals up to 3mg daily. A therapeutic effect is observed at doses of 3-9mg daily. If symptoms are not adequately controlled or symptom control is not maintained, the ropinirole dose may be increased until a clear therapeutic effect is achieved, but it should not exceed 24mg daily. 2. When administered as adjunctive therapy to levodopa, the levodopa dose may be gradually reduced by up to approximately 20% of the total dose. 3. When switching from another dopamine agonist to ropinirole, follow the manufacturer's guidelines for discontinuing the other medication before starting ropinirole. 4. As with other dopamine agonists, ropinirole should be discontinued gradually by reducing the number of daily doses over the course of 1 week. (See section ‘4. General precautions’ under Precautions for use.) 5. Administration to patients with mild or moderate renal impairment (creatinine clearance 30-50mL/min): No dose adjustment is necessary because ropinirole clearance is unchanged. 6. Patients with severe renal impairment (creatinine clearance ＜30mL/min) or hepatic impairment: Administration of ropinirole is not recommended. 7. Administration to elderly patients: Ropinirole clearance is reduced in patients aged 65 years or older, but the dose for elderly patients can be adjusted in the usual manner.

Child dose

8. Pediatric use: Parkinson's disease does not occur in children. Therefore, no studies on the use of ropinirole in this population have been reported, and it should not be administered to children.

This medication should be used with caution in patients with severe cardiovascular disease. There is a risk of cardiac issues such as hypotension or bradycardia when used with other antihypertensives or antiarrhythmics. Patients with significant mental illness should carefully consider the risks and benefits before using this medication. As this medication may cause sudden sleep episodes, caution is advised during activities requiring alertness, such as driving or operating machinery. This medication should not be used by individuals with hypersensitivity to it, or by pregnant or breastfeeding women. Additionally, patients with lactose intolerance should not take this medication. Side effects such as nausea, drowsiness, dizziness, abdominal pain, constipation, hallucinations, confusion, and orthostatic hypotension may occur, and if any abnormal symptoms arise, medical consultation should be sought immediately. Particularly in Parkinson's disease patients, motor symptoms may arise, necessitating dosage adjustments. It is advisable not to use this medication in conjunction with other dopamine agonists and to inform about any concurrent medications, as this drug may interact with certain substances. Pregnant or nursing women should not use this medication and its use is not recommended for children under 18 years due to safety concerns. In cases of overdose, symptoms such as nausea, dizziness, hallucinations, chorea, and palpitations may occur, requiring immediate emergency care. This medication should be stored out of the reach of children and kept in a cool, dry place, away from direct sunlight.

• Dizziness
• drowsiness
• leg swelling
• abdominal pain
• vomiting
• loss of consciousness
• abnormal movements
• hallucinations
• confusion
• vertigo

This medication should be stored at a cool temperature below 25 degrees Celsius and in a tightly closed container that is protected from light and well-ventilated. Proper storage will help maintain the medication's efficacy and prevent degradation.

Appearance

Light blue film-coated tablets in a pentagonal shape with 'SB' engraved on one side and '4894' engraved on the other side, both sides are convex.

Package unit

21 tablets/PTP